Journal article

Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art

Zheng Quan Toh, Paul V Licciardi, James Fong, Suzanne M Garland, Sepehr N Tabrizi, Fiona M Russell, Edward K Mulholland

Vaccine | ELSEVIER SCI LTD | Published : 2015


Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer requires the prevention of high-risk HPV infections, particularly HPV genotypes 16 and 18. Both Gardasil® and Cervarix® vaccines when administered by a three-dose schedule have been demonstrated to be effective against cervical, vulva, and vaginal cancer precursors from vaccine genotypes in phase III clinical trials, and post-marketing studies; Gardasil® vaccine also offers additional protection against anal cancer precursors. However, high costs of HPV vaccines and the..

View full abstract


Funding Acknowledgements

The work was part of the New Vaccine Evaluation Project (NVEP), funded by the Fiji Health Sector Support Project and Australian Aid-JTA, the Department of Foreign Affairs and Trade, Australia. ZQT is supported by a Melbourne Research Scholarship from The University of Melbourne and a Murdoch Childrens Research Institute top-up scholarship. FMR is a recipient of an NHMRC Early Career Fellowship. This work was also supported in part by the Victorian Government's Operational Infrastructure Support Program.